Biomarkers
Prognostic significance of inflammation scores in malignant mesothelioma
European Review for Medical and Pharmacological Sciences 2024 March [Link] E Mutlu, M Inanc Abstract Objective: The relationship between inflammatory markers and survival in many cancers has been investigated previously. Inflammatory markers may also offer the possibility of predicting surveillance in patients with malignant mesothelioma. Our study seeks to enhance comprehension of how variables such…
Read MoreCHST4 Gene as a Potential Predictor of Clinical Outcome in Malignant Pleural Mesothelioma
International Journal of Molecular Sciences 2024 February 14 [Link] Shoji Okado, Taketo Kato, Yuki Hanamatsu, Ryo Emoto, Yoshito Imamura, Hiroki Watanabe, Yuta Kawasumi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Tamotsu Takeuchi, Shigeyuki Matsui, Toyofumi Fengshi Chen-Yoshikawa Abstract Malignant pleural mesothelioma (MPM) develops primarily from asbestos exposures and has a poor prognosis. In this…
Read MoreBAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma
Journal of Cancer Research and Clinical Oncology 2024 January 27 [Link] Tuna Han Yuce, Guntulu Ak, Selma Metintas, Emine Dundar, Oluf Dimitri Roe, Vasiliki Panou, Muzaffer Metintas Abstract Purpose: There are currently no methods to predict response to chemotherapy in pleural mesothelioma (PM). The aim of this study is to investigate the predictive and prognostic…
Read MoreNovel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1
International Journal of Cancer 2024 January 11 [Link] Taku Kouro, Naoko Higashijima, Shun Horaguchi, Yasunobu Mano, Rika Kasajima, Huihui Xiang, Yuki Fujimoto, Hiroyuki Kishi, Hiroshi Hamana, Daisuke Hoshino, Hidetomo Himuro, Rieko Matsuura, Shoutaro Tsuji, Kohzoh Imai, Tetsuro Sasada Abstract The selection of highly specific target antigens is critical for the development of clinically efficient and…
Read MorePD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma
Frontiers in Oncology 2023 December 4 [Link] Alejandro Avilés-Salas, Luis Cabrera-Miranda, Norma Hernández-Pedro, Diana Sofía Vargas-Lías, Suraj Samtani, Wendy Muñoz-Montaño, Daniel Motola-Kuba, Luis Corrales-Rodríguez, Claudio Martín, Andrés F Cardona, Cittim B Palomares-Palomares, Oscar Arrieta Abstract Background: Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant…
Read MoreMethylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma
Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…
Read MoreAnalysis of Ki67 Protein Expression and Clinicopathological Features in Patients with Peritoneal Mesothelioma
Alternative Therapies in Health and Medicine 2023 December 8 [Link] Dujuan Yang, Yeping Zhou, Kongdan Lv Abstract Background: At present, there are many treatments for peritoneal mesothelioma, but the treatment of peritoneal mesothelioma is still facing great challenges. Distant metastasis is the main cause of poor prognosis and death of patients with peritoneal mesothelioma. Ki67…
Read MoreLAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study
BMC Cancer 2023 December 7 [Link] Ken Arimura, Kenzo Hiroshima, Yoji Nagashima, Tadao Nakazawa, Akira Ogihara, Mami Orimo, Yasuto Sato, Hideki Katsura, Masato Kanzaki, Mitsuko Kondo, Etsuko Tagaya Abstract Background: Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint receptor; novel LAG3 immune checkpoint inhibitors (ICIs) exhibit therapeutic activity in melanoma. The role of LAG3and ICIs…
Read MoreCombined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
Cancer Research Communications 2024 January 3 [Link] Jitendra Badhai, Nick Landman, Gaurav Kumar Pandey, Ji-Ying Song, Danielle Hulsman, Oscar Krijgsman, Gayathri Chandrasekaran, Anton Berns, Maarten van Lohuizen Abstract Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using…
Read MoreFormalin-Fixed Paraffin-Embedded Proteomics of Malignant Mesothelioma and New Candidate Biomarkers Thioredoxin and Superoxide Dismutase 2 for Immunohistochemistry
Laboratory Investigation 2023 November [Link] Takuya Hiratsuka, Akihiko Yoshizawa, Tatsuya Endo, Takushi Yamamoto, Shinya Toyokuni, Tatsuaki Tsuruyama Abstract The pathogenesis of malignant mesothelioma (MM) has been extensively investigated, focusing on stress derived from reactive oxygen species. We aimed to identify diagnostic biomarkers of MM by analyzing proteins in formalin-fixed paraffin-embedded specimens using liquid chromatography-mass spectrometry.…
Read More